Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do's and don'ts from the ECCO-COVID Taskforce

Conflict of InterestECCO has diligently maintained a disclosure policy of potential conflicts of interests. The conflict of interest declaration is based on a form used by the International Committee of Medical Journal Editors. The conflict of interest statement is not only stored at the ECCO Office and the editorial office of Journal of Crohn's and Colitis, but also open to public scrutiny on the ECCO website [https://www.ecco-ibd.eu/about-ecco/eccodisclosures.html] providing a comprehensive overview of potential conflicts of interest of authors.AbstractOur knowledge on COVID-19 is changing and evolving rapidly, with novel insights and recommendations, almost on a daily basis. It behooves the medical community to provide updated information on a regular basis, on best practice to facilitate optimal care of infected patients and appropriate advice for the general population. This is particularly important in the case of patients with chronic conditions, such as Inflammatory Bowel Disease (IBD).In this paper, we compiled the existing evidence on the impact of COVID-19 in IBD patients and provide guidance and on the most appropriate care to adopt during the pandemic. Our review highlighted that IBD, per se, is not a risk factor for COVID-19.However, all IBD patients with symptoms should be tested for SARS-CoV-2 and the procedures for disease management shall be carefully adapted: i) in SARS-CoV-2 positive IBD patients, medical treatments should be re-evaluated (with particular focus on corticosteroids) always with the purpose of treating active disease and maintaining remission; ii) non-urgent surgeries and endoscopic procedures should be postponed for all patients; iii) online consultancy should be implemented; and iv) hospitalization and surgery should be limited to life threatening situations.

# Introduction
At the end of 2019, a cluster of patients with pneumonia emerged in Wuhan, Hubei Province, China, with possible zoonotic origin. [bib_ref] Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia, Li [/bib_ref] This unidentified pneumonia was later found to be related to a novel coronavirus (CoV) 2 named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by the International Committee on Taxonomy of Viruses (ICTV).To prevent the use of inaccurate or stigmatizing names, the World Health Organization (WHO) proposed a standard format for the disease nomenclature:
COronaVIrus Disease-2019 .SARS-CoV-2 is a single positive-stranded RNA virus enveloped in a lipid bilayer. The virus sneaks into the human body via the mucous membranes (mouth, nasal, ocular) and enters host cells through the binding of viral spike proteins (S-protein) to the human protein receptor angiotensin converting enzyme-2 (ACE2). [bib_ref] A novel coronavirus outbreak of global health concern, Wang [/bib_ref] This receptor is abundant in lung, heart, kidney, adipose tissue, esophagus, stomach, bladder, ileum, and colon. [bib_ref] ACE2: from vasopeptidase to SARS virus receptor, Turner [/bib_ref] [bib_ref] Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential..., Zou [/bib_ref] Transmission of COVID-19 is efficient. Aerosol and fomite transmission of SARS-CoV-2 is plausible, since the virus can remain viable and infectious in aerosols for hours, and on surfaces up to days (depending on the inoculum shed). In fact, the concentration of viral RNA in airborne samples is minimal or close to zero, but it can be detected on fomites including plastic. [bib_ref] Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1, Van Doremalen [/bib_ref] Transmission occurs from close contact and respiratory droplets, without evidence of airborne transfer [bib_ref] Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1, Van Doremalen [/bib_ref]. Thus, people who are in close contact with patients, their family members or healthcare workers are part of the high-risk population. [bib_ref] Pathogenesis, and Control of COVID-19, Jin [/bib_ref] The spread of SARS-CoV-2 identifed two important modes of disease transmission: i) local transmission, at each local epicenter; and ii) transmission via international travelers which favored the global spread of the infection, fueling COVID-19 pandemic. Large outbreaks were reported in closed communities and hospitals, raising the possibility of 'superspreading' events, as reported before in previous CoV outbreaks. [bib_ref] The daily impact of COVID-19 in gastroenterology, Magro [/bib_ref] By May 2020, M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjaa160 the pandemic had affected almost 2 million people, worldwide, accounting for over 125,000 deaths, with the numbers rising sharply (Worldometer's COVID-19 data).SARS-CoV-2 infection is associated with five different clinical courses: asymptomatic infection, mild to medium cases, severe cases, critical cases and death. [bib_ref] Pathogenesis, and Control of COVID-19, Jin [/bib_ref] While highly transmissible, more than 80% of the patients have mild disease. [bib_ref] Management of IBD during the COVID-19 outbreak: resetting clinical priorities, Danese [/bib_ref] In the face of these challenging circumstances, gastroenterologists need to adapt priorities, reset standards of quality of care, and guide patients by providing relevant information.
In this context, the European Crohn's and Colitis Organization (ECCO) gathered a group of gastroenterologists, with particular interest in opportunistic infections, and infectious disease experts, to deliver guidance to physicians in the setting of gastrointestinal (GI) diseases during COVID-19 pandemic. The aim of the current paper is to provide health care professionals with understanding and knowledge of the optimal care we can provide to our patients, including those taking immunomodulatory treatment.
According to and to the European Centre for Disease Prevention and Control (ECDC), social distancing, hand hygiene and respiratory etiquette should be adopted by all the population to prevent the spread of the infection. Hand hygiene is considered to be

## 1-general measures
Do's  Do avoid contact with infected people  Do avoid touching eyes, nose or mouth with unwashed hands  Do clean hands using soap and water or an alcohol-based solution  Do avoid crowded places  Do use face masks according to local policies  Do ensure flu vaccine for all non-vaccinated IBD patients  Do ensure pneumococcal vaccination for all non-vaccinated IBD patients  Do discourage travelling M a n u s c r i p t Such measures include routine cleaning of frequently used surfaces and objects (phones, tablets, keyboards), and minimizing the sharing of objects 17 (ECDC). Surgical masks may be used as an infection control measure or as a mitigation measure, in community settings, when used by individuals with respiratory symptoms but that did not seek medical attention yet. People at high risk of exposure include care providers with extensive face-to-face contact. A recent meta-analysis on influenza prevention suggested that N95 respirators should not be recommended to general public and low risk medical staff. [bib_ref] Effectiveness of N95 respirators versus surgical masks against influenza: A systematic review..., Long [/bib_ref] Travelling should be limited, for everyone, as much as possible, with the aim of reducing: i) acquisition of infection by travelers to areas or countries where community transmission is ongoing; ii) importation of cases from affected countries; and iii) transmission among travelers.
Patients with IBD, taking immunomodulatory therapy, have increased risk of influenza and pneumococcal disease. [bib_ref] Increased Risk of Influenza and Influenza-Related Complications Among 140,480 Patients With Inflammatory..., Tinsley [/bib_ref] [bib_ref] Inflammatory Bowel Disease Patients Are at Increased Risk of Invasive Pneumococcal Disease:..., Kants [/bib_ref] To avoid pulmonary comorbidities with influenza and pneumococcal disease during this outbreak, and next winter, all IBD patients should be vaccinated. Influenza and pneumococcal vaccination are recommended for the majority of patients with immune mediated disorders, including IBD. [bib_ref] Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic..., Rahier [/bib_ref] Since influenza infection rates can be reduced by annual vaccination, flu vaccine is recommended in all non-vaccinated IBD patients, and especially during COVID-19 pandemic. Although not numerous, some cases of influenza coinfection with SARS-CoV-2 have been described. [bib_ref] The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and..., Ding [/bib_ref] [bib_ref] Paniz Mondolfi AE. Co-infection in SARS-CoV-2 infected Patients: Where Are Influenza Virus..., Nowak [/bib_ref] During the next seasonal outbreak, SARS-CoV-2 and influenza are likely to occur simultaneously. Patients who have not been previously vaccinated for Streptococcus pneumoniae, should receive a dose of PCV13 followed by a dose of PPSV23, at least 8 weeks later. [bib_ref] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among..., Matanock [/bib_ref] So far, IBD patients have not shown increased susceptibility to COVID-19 [bib_ref] Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the..., Allocca [/bib_ref] [bib_ref] Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China, An [/bib_ref]. This is clearly evidenced in very recent studies, in Spanish, French and Italian IBD cohorts studied, in which the risk of infection, associated mortality and incidence of COVID-19 were similar to those reported for the general population. [bib_ref] Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the..., Allocca [/bib_ref] A recent study from Wuhan, performed during the local outbreak of the disease, including 318 patients with IBD, did not report a single COVID-19 case. [bib_ref] Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China, An [/bib_ref] However, all biological and immunomodulatory treatments were discontinued rendering interpretation difficult. [bib_ref] Inflammatory bowel diseases and COVID-19: the invisible enemy, D&apos;amico [/bib_ref] The therapeutic approach for these patients should instead consider the risk of viral infection weighed against the risk 2-Should we stop drugs in patients without symptoms suggestive of COVID-19 (not tested or tested negative)? Do's  Do continue immunomodulators  Do continue biologics  Do continue JAK inhibitors  Do reduce corticosteroids whenever possible  Do keep infusions in an infusion center whenever possible Don'ts  Don't reduce the dose of immunomodulators or biologics to prevent SARS-CoV-2 infection  Don't switch infliximab to adalimumab in a stable patient, unless it is not possible to provide intravenous infusions  Don t assume that IBD patients are at increased risk of being infected Don't Know  Patients with IBD, who are exposed to SARS-CoV-2, have a higher risk of developing symptomatic or severe COVID-19 M a n u s c r i p t immunomodulators, anti-TNF therapy, anti-integrins and anti-Il12/23 were not associated with increased mortality.Therefore, in balance, we believe that immunomodulatory drugs should be maintained in IBD patients without COVID-19 infection.
There are biological reasons to support why COVID-19 may not pose increased risk to IBD patients on immunomodulatory therapy. First, it has been suggested that the soluble form of ACE2 acts as a competitive binding partner for SARS-CoV-2 sequestring the virus, hindering binding to the virus's cell surface receptor, the full-length ACE2 protein. [bib_ref] COVID-19 spike-host cell receptor GRP78 binding site prediction, Ibrahim [/bib_ref] [bib_ref] Covid-19 and immunomodulation in IBD, Neurath [/bib_ref] Elevated levels of ACE2 were measured in the plasma from patients with IBD 36 with evidence of limited infection progression and low susceptibility to infection. [bib_ref] Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?, Batlle [/bib_ref] The role of A c c e p t e d M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjaa160
ACE2 was also evidenced through the use of a chemical inhibitor of ACE2 (GL1001), that was able to reduce dextran sulfate sodium (DSS) colitis severity, in the mouse model, suggesting that ACE2 plays a pathogenic role in colitis. [bib_ref] Covid-19 and immunomodulation in IBD, Neurath [/bib_ref] Second, tumor necrosis factor (TNF) inhibitors might be effective in reducing organ damage.This effect is achieved through the decreased shedding of the ACE2 ectodomain (mediated by TNF--converting enzyme) which is essential for the penetration of SARS-CoV-2 into the cell. Third, as IFN and TNF production has been associated with severe SARS-CoV infection, inhibition of TNF has been proposed as a treatment for the cytokine release syndrome that can occur in some of these patients. [bib_ref] Cell Responses to Whole SARS Coronavirus in Humans, Li [/bib_ref] Fourth, mercaptopurine and 6-thioguanine have potential antiviral activity against MERS and SARS, at least in vitro. [bib_ref] Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle..., Cheng [/bib_ref] Fifth, tacrolimus is a potent in vitro antiviral for human coronaviruses. [bib_ref] Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine..., Carbajo-Lozoya [/bib_ref] Sixth, most of the drugs used in IBD have a long elimination half-life and keep some activity even after treatment cessation. [bib_ref] Management of Patients with Crohn's Disease and Ulcerative Colitis During the COVID-19..., Rubin [/bib_ref] Seventh, viral infections did not increase among IBD patients receiving ustekinumab and vedolizumab therapy. In addition, in a phase I clinical trial, the viral load of HIV patients on vedolizumab did not change significantly. In conclusion, the available data suggest that immunosuppressed patients are not at increased risk for severe disease and complications, compared with the general population.
In circumstances where it is not possible to safely run an infusion service, it may be reasonable to consider switching to sub-cutaneous alternatives. However, this practice must be used judiciously since elective switching from infliximab to adalimumab is associated with a loss of tolerance and efficacy within 1 year. [bib_ref] Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab:..., Van Assche [/bib_ref] A c c e p t e d M a n u s c r i p t M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjaa160 admission (19%) and death (11%); although this data is currently unadjusted for age or comorbidity.Concerning SARS-CoV-2 infection, steroids were not effective for the treatment of lung injury or shock. [bib_ref] Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, Russell [/bib_ref] However, short-term steroids ( 0.5-1 mg/kg for 7 days) may be beneficial to control overwhelming inflammation and cytokine-related lung injury, particularly in severe forms of ARDS. [bib_ref] Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia, Zhou [/bib_ref] [bib_ref] On the use of corticosteroids for 2019-nCoV pneumonia, Shang [/bib_ref] [bib_ref] Surviving Sepsis Campaign: guidelines on the management of critically ill adults with..., Alhazzani [/bib_ref] Data on low-dose and short-term steroids, budesonide and beclomethasone therapy are not currently available.
The first analysis of the SECURE-IBD data also identified 5-ASAs as a risk for severe VZV, HSV), mostly in patients exposed to thiopurines.This can be related to the ability of azathioprine/6-mercaptopurine and tofacitinib to reduce the number of activated T cells and affect T-cell activation and effector function. [bib_ref] Covid-19 and immunomodulation in IBD, Neurath [/bib_ref] Tofacitinib has also been associated with viral infections (VZV) [bib_ref] A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in..., Sandborn [/bib_ref] and demonstrated inhibition of interferon- production in vitro. [bib_ref] JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits..., Boor [/bib_ref] The decision to pharmacologically immunosuppress a patient with COVID-19 remains difficult. The possible beneficial effects in reducing inflammation should be carefully weighed against the potential deleterious impairment of anti-microbial immunity.
A c c e p t e d M a n u s c r i p t The maximal viral shedding of SARS-CoV-2 occurs in the early stages of infection, meaning that spreading from asymptomatic patients is a reality. In hospitals and clinics caring for a large number of COVID-19 patients, the rate of infection is high among health

## 5-how can we continue iv infusion clinics?
Do's  Do implement screening procedures for suspected COVID-19 in all patients  Do implement measures to minimize crowding  Do implement at least 2m distance between chairs  Do impose the use of surgical face masks in all patients  Do continue biologics at regular intervals and doses Don'ts  Don't switch infliximab to adalimumab in stable patients unless it is not possible to provide intravenous infusions  Don't allow accompanying persons inside the hospital workers. [bib_ref] Clinical characteristics of 80 hospitalized frontline medical workers infected with COVID-19 in..., Wang [/bib_ref] In IV infusion clinics, the first measure is to identify the patients who are possibly infected, since the approach and safety requirements will be different. Thus, symptomatic (fever, cough, fatigue, myalgia, expectoration, diarrhea, and loss of sense of smell or taste) or suspected (contact with a positive person) patients should be promptly tested and submitted to protective measures. The use of masks, in patients attending hospitals, is highly recommended, even in those without symptoms.populations. In fact, faecal calprotectin levels showed a significant correlation with endoscopic extent, mucosal healing, and histological activity. [bib_ref] Review article: faecal calprotectin and histologic remission in ulcerative colitis, D&apos;amico [/bib_ref] [bib_ref] Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical..., Magro [/bib_ref] Moreover, non-invasive imaging, such as ultrasonography, is essential for diagnosis and monitoring because it is a low risk procedure with the advantage of providing a rapid assessment of disease activity (location, extension, inflammation, and presence of complications like fistula, strictures or intrabdominal abscesses). [bib_ref] Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period, Iacucci [/bib_ref] A c c e p t e d M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjaa160
In the case of patients enrolled in clinical trials before the outbreak, the sponsors can be asked to: i) postpone non-necessary follow-up visits or to replace them by virtual clinics; ii) identify local labs that can guarantee the regular lab tests required by the protocol; iii) manage home delivery of study drugs, mainly those of oral and subcutaneous administration. In this scenario, patients would go to the hospital only for key visits (end of induction, re-randomization, end of study) and to receive intravenous drugs, when these cannot be suspended. The administration of intravenous drugs can also be adapted, mainly regarding dose intervals. For instance, infliximab administration can be postponed to every 10 weeks. [bib_ref] De-escalation of Infliximab Maintenance Therapy from 8-to 10-week Dosing Interval Based on..., Papamichael [/bib_ref] Regarding vedolizumab, the GEMINI trial showed that patients randomized to placebo can maintain remission up to week 24. Therefore, postponing vedolizumab 4-8 weeks may be reasonable. However, maintaining the original schedule remains the best strategy in most cases.
IBD patients on immunomodulators do not seem to have a higher risk of infection than the rest of the population. However, due to disease specificities and possible side effects of the treatment, avoidance of SARS-CoV-2 requires an additional set of precautions.
Thus, patients should take extra protective measures, over and above those of the general population. Some societies use the concept of "stringent social distancing" and "shielding", with measures ranging from avoidance of crowded places to advice to not leave the house Endoscopy should be performed in a negative-pressure room, if possible, in accordance with the guidelines for infection control in endoscopy. [bib_ref] Reprocessing of flexible endoscopes and endoscopic accessories used in gastrointestinal endoscopy: Position..., Beilenhoff [/bib_ref] [bib_ref] ASGE guideline for infection control during GI endoscopy, Calderwood [/bib_ref] In addition, the staff of the endoscopy department should follow standardized precautions. 12 SARS-CoV-2 is easily inactivated by many common disinfectants and no additional approach should be implemented to clean and disinfect the endoscope. [bib_ref] Human Coronaviruses: Insights into Environmental Resistance and Its Influence on the Development..., Geller [/bib_ref] Even so, due to the risk of aerosolization, the room should be kept empty for at least for 1 hour before the next procedure in the absence of negative pressure, and for 30 minutes in the case of a negative-pressure room. [bib_ref] COVID-19) outbreak: what the department of endoscopy should know, Repici [/bib_ref] The basic protection requirements of the medical staff, in the endoscopy centre, should reach Biosafety level 2 (wearing of disposable gowns, N95
A c c e p t e d M a n u s c r i p t Emergency surgery is required in life-threatening situations, such as bowel perforation, closed loop, or medically refractory acute severe colitis. Conversely, non-urgent surgery should be postponed to protect patients and healthcare workers, and facilitate the management of healthcare resources, in times of scarcity of staff and material. [bib_ref] Global guidance for surgical care during the COVID-19 pandemic, Covids [/bib_ref] [bib_ref] Managing COVID-19 in Surgical Systems, Brindle [/bib_ref] Non-elective surgery is indicated for invasive colorectal cancer/high-grade dysplasia, intractable stenosis, and abdominal/perianal abscesses not amenable to medical/interventional management. [bib_ref] International Organization for the Study of Inflammatory Bowel Disease Recommendations for Surgery..., Remzi [/bib_ref] Perioperative complexity should be minimized, including liberal use of terminal ostomy instead of a high-risk anastomosis, and drainage procedures, with or without antibiotics, instead of complex surgery. [bib_ref] International Organization for the Study of Inflammatory Bowel Disease Recommendations for Surgery..., Remzi [/bib_ref] Keeping track of deferred surgeries is the key to provide responsible surgical care after the pandemic.
Owing to the paucity of symptoms in the majority of COVID-19-positive patients and to the surgical morbidity reported during viral incubation (mortality 20.5%, ICU requirement

## 10-can we still perform ibd surgery?
Do's  Do emergency surgery in life-threatening situations  free bowel perforation  closed loop obstruction  acute severe colitis refractory to medical treatment  active bleeding not amenable to interventional therapy  Do non-elective surgery as soon as possible  invasive colorectal cancer, high-grade dysplasia  intractable stenosis failing medical management  penetrating luminal disease resistant to medical therapy  perianal abscesses  Do postpone surgery in uncomplicated IBD  Do test all IBD patients with SARS-CoV-2-PCR before any surgery  Do use N95 respirators as a minimal requirement for surgery Don'ts  Don't perform non-urgent IBD surgery A c c e p t e d M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjaa160 44.1%), it is mandatory to test all patients for SARS-CoV-2 before surgery. [bib_ref] COVID-19 Outbreak and Surgical Practice, Aminian [/bib_ref] When rapid PCR tests are unavailable, chest CT can be the diagnostic. If neither testing nor imaging is available, all patients must be considered positive. [bib_ref] International Organization for the Study of Inflammatory Bowel Disease Recommendations for Surgery..., Remzi [/bib_ref] At surgery, the risk of aerosolization is high and contamination with body fluids is a concern. 93 To date, infectious virus was found in airway, blood, and feces.Aerosol formation is potentiated by tissue dissection with energy devices, while concentration of abdominal aerosol is inherent to laparoscopy. [bib_ref] Protecting Surgical Teams During the COVID-19 Outbreak, Brat [/bib_ref] [bib_ref] COVID-19 & the General Surgical Department -Measures to Reduce Spread of SARS-COV-2..., Yeo [/bib_ref] [bib_ref] Minimally Invasive Surgery and the Novel Coronavirus Outbreak: Lessons Learned in China..., Zheng [/bib_ref] Consequent use of PPE is mandatory, including face shield/googles, N95 mask, and proper donning and doffing. [bib_ref] Protecting Surgical Teams During the COVID-19 Outbreak, Brat [/bib_ref] The number of staff should be minimized and negative pressure operating rooms should be preferred.
Scientific societies have issued conflicting statements regarding the use of laparoscopy, with no firm contraindication in the COVID-19 era. Avoidance of laparoscopy is thus debatable, as open surgery will translate in additional morbidity and resource utilization.
Low energy setting and pneumoperitoneum pressure, avoidance of 2-way insufflators, closed circulation with efficient filtration of pneumoperitoneum, and gentle desufflation are advised. [bib_ref] What Is the Appropriate Use of Laparoscopy over Open Procedures in the..., Vigneswaran [/bib_ref] 

# Conclusions
In conclusion, the existing evidence shows that IBD is not a risk factor for COVID-19.
However, medical treatments should be re-evaluated in SARS-CoV-2 positive IBD patients and corticosteroid therapy should be re-evaluated regardless of symptoms. A goal should be to treat active disease and maintain remission, while adopting the same protective measures as the general population. In addition, non-urgent surgeries and endoscopic procedures should be postponed.
A c c e p t e d M a n u s c r i p t
[fig] 6 -: Do patients need specific protective equipment? Do physicians need specific equipment when seeing IBD patients? Do's  Do avoid close contact with people and wash hands frequently  Do use face masks (patient and physician) Don'ts  Don't see patients with accompanying persons unless strictly necessary7-How to manage outpatient IBD clinics?Do's  Do implement telemedicine  Do monitor at distance  Do web report outcomes  Do promote local labs with e-mail reports  Do implement point-of-care biomarkers  Do implement calprotectin measurement at home  Do implement measure of drug levels (TDM) with rapid tests  Do cross sectional imaging, including intestinal ultrasound instead of invasive procedures Don'ts  Don't hospitalize patients unless strictly necessary  Don't schedule unnecessary appointments, limit to what is strictly decision-making [/fig]
[fig] 8 -: Can IBD patients on immunomodulator/biological treatment continue working? What about Health Care professionals with IBD? Do's  Do avoid contact with infected patients  Do use masks when working  Do redirect towards the lowest risk zones  Favor teleworking when possible not rare to find IBD patients working in health care systems. Considering that this population experiences higher rates of infections than general population, it may be necessary to introduce extra precautions in health care workers with IBD. If possible, these professionals should be redirected from high risk areas (like emergency departments, infectious disease units, and intensive care units) to low risk areas and, when possible, working from home should be implemented. Protective Personal Equipment (PPE) should be used according to international guidelines, when homeworking is not viable. 9-Can we perform non-urgent endoscopy? If not, what is non-urgent endoscopy? Do's  Do perform endoscopy as priority 3 months after the infection rates decrease  IBD patients with mild-moderate flare-up confirmed by biomarkers, to exclude CMV infection  Longstanding IBD in surveillance for CRC, if prior dysplasia  Endoscopic resection in IBD patients known to have LGD/HGD colonic lesions already detected  Do perform endoscopy within 3-6 months after the infection rates decrease  Pouchitis  IBD patients with flare-up not confirmed by biomarkers  Longstanding IBD in surveillance for CRC Dont's  Don't perform non-urgent endoscopy  Don't use surgical masks in the endoscopy room [/fig]